Zafirlukast: An update of its pharmacology and therapeutic efficacy in asthma

Drugs

Volumn 61, Issue 2, 2001, Pages 285-315

  Dunn, C J ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; ERYTHROMYCIN; FLUTICASONE PROPIONATE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; PLACEBO; PRANLUKAST; SALMETEROL; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ADOLESCENT; ADULT; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEROID THERAPY;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0035105775     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161020-00012     Document Type: Review

References (150)

1. Zafirlukast: A review of its pharmacology and therapeutic potential in the management of asthma
2. Liberation of histamine and formation of lysocithin-like substances by cobra venom
3. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock
4. Role of phospholipase in generating lipid second messengers in signal transduction
5. 2
6. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leucocytes
7. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
8. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alvcolar macrophages
9. 4
10. Recombinant mouse leukotriene A4 hydrolase: A zinc metalloenzyme with dual enzymatic activities
11. 4 by human eosinophils
12. 4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport
13. Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature
14. Characterization of the human cysteinyl leukotriene 2 receptor
15. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor
16. Leukotrienes are potent constrictors of human bronchi
17. Bronchoconstrictor effects of leukotriene C in humans
18. Effects of leukotriene D on the airways in asthma
19. 4, and histamine in normal human subjects
20. 4. Endothelial contraction
21. 4 increase the release of mucus from human airways in vitro
22. 4 and granulocytic infiltration into asthmatic airways
23. Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate™)
24. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy
25. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis
26. The preclinical pharmacology of ICI 204,219: A peptide leukotriene antagonist
27. 4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI 204,219
28. 4)-induced bronchoconstriction in patients with asthma
29. 4 receptor antagonist ICI 204,219
30. 4)-induced bronchoconstriction in asthmatic patients receiving inhaled corticosteroids
31. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics
32. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma
33. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction
34. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
35. 4 receptor antagonist
36. 4 receptor antagonist ICI 204,219 against exercise-induced asthma
37. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children
38. Effects of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma
39. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma
40. Effect of zafirlukast (20 and 40mg) on cold-air-induced bronchoconstriction in patients with bronchial asthma
41. Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction
42. Effect of Accolate™ (zafirlukast) on sulfur dioxide (SO2)-induced bronchoconstriction in patients with mild to moderate asthma
43. 4 receptor antagonist IC1 204,219
44. 4) induced airway inflammation in asthma
45. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge
46. Effect of zafirlukast (Accolate®) on pulmonary responses to natural cat allergen exposure
47. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions
48. Mucosal inflammation in asthma
49. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
50. Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma
51. 2-adrenoceptor genotype
52. Effect of low dose inhaled fluticasone propionate (FP) and oral zafirlukast (ZK) on exhaled nitric oxide (ENO) in Hispanic asthmatics
53. Zafirlukast
54. Accolate
55. Accolate (zafirlukast) tablets. Professional information brochure
56. Lack of interaction between zafirlukast and theophylline in children
57. An alarming drug interaction between zafirlukast and theophylline
58. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers
59. 4 receptor antagonist, in subjects with bronchial asthma
60. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction
61. Zafirlukast (Accolate®) response in severe persistent asthma
62. Global initiative for asthma. Global strategy for asthma management prevention
63. Zafirlukast in a case of severe eczema with hyper-IgE
64. Improvement of atopic eczema with a leukotriene inhibitor: A new therapeutic use?
65. Zafirlukast (Accolate) in the treatment of chronic idiopathic urticaria - A case series
66. Antileukotrienes in chronic urticaria
67. Leukotriene pathway modifiers: Are they the newest line of therapy for chronic sinusitis?: Case reports
68. Nasal function is improved by zafirlukast (20mg bid x 4wks) in ASA-sensitive rhinitis
69. The first successful experience of applying zafirlukast in patients with allergic rhinosinusitis and mild-to-moderate asthma in Russia
70. Resolution of chronic nasal polyps by zafirlukast
71. Treatment of refractory nasal polyps with leukotriene inhibitors/antagonists
72. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis
73. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
74. Onset of action of the leukotriene-receptor antagonist, zafirlukast, in patients with asthma
75. Reference spirometric values using techniques and equipment that meets ATS recommendations
76. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses
77. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma
78. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: An integrated analysis of zafirlukast trials
79. Efficacy and safety of zafirlukast (Accolate™) in asthmatic patients treated with and without corticosteroids
80. Long-term safety and efficacy of zafirlukast in the treatment of asthma: Interim results of an open-label extension trial
81. Zafirlukast improves asthma control in children treated with and without inhaled corticosteroids
82. Long-term safety and efficacy of zafirlukast (Accolate) in pediatric patients with mild-to-moderate asthma
83. Long-term safety and effectiveness of zafirlukast in school-aged children with asthma
84. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children
85. Management of asthma. The potential role of zafirlukast
86. Addition of zafirlukast compared with a doubled dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids
87. Addition of zafirlukast (Accolate™) compared with a double-dose of inhaled corticosteroids in patients with reversible airways obstruction symptomatic on inhaled corticosteroids
88. Effects of Accolate™ (zafirlukast; 20 mg bd) in permitting reduced therapy with inhaled steroids: A multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day
89. A multicentre study to assess the steroid-sparing potential of Accolate™ (zafirlukast; 20 mg BD)
90. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
91. Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages ≤500 μg/day in adults and adolescents with mild to moderate asthma
92. Low-dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients
93. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
94. Switching asthma patients from low dose inhaled corticosteroids to low dose fluticasone or zafirlukast
95. Fluticasone propionate compared to zafirlukast in the treatment of persistent asthma
96. Inhaled fluticasone propionate versus oral zafirlukast in asthma patients
97. Better asthma symptom control with low-dose inhaled fluticasone propionate than with oral zafirlukast
98. Low-dose fluticasone versus zafirlukast in patients with persistent asthma
99. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma
100. Third international pediatric consensus statement on the management of childhood asthma
101. Summary of recommendations from the Canadian Asthma Consensus Report, 1999
102. Salmeterol: A review of its pharmacological properties and clinical efficacy in the management of children with asthma
103. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
104. A comparison of salmeterol and zafirlukast in patients with persistent asthma
105. A comparison of salmeterol versus zafirlukast in patients using inhaled corticosteroids
106. Phase III comparative study of ICI 204,219 (zafirlukast, Accolate), a cysteinylleukotriene (LT) receptor antagonist, in adult patients with bronchial asthma: Double-blind comparative study with pranlukast hydrate
107. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT)
108. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: A randomized, double-blind, placebo-controlled trial
109. Cost impact of reducing exacerbations of asthma in multi-national clinical trials with zafirlukast
110. Cost effectiveness of inhaled fluticasone versus zafirlukast in patients switched from low dose inhaled corticosteroids
111. A cost effectiveness analysis of inhaled fluticasone propionate (Flovent) versus zafirlukast (Accolate) in the treatment of patients with persistent asthma
112. Cost-efficacy analysis of an inhaled corticosteroid versus a leukotriene receptor antagonist
113. Costefficacy of an inhaled corticosteroid, fluticasone propionate, and an oral leukotriene modifier, zafirlukast, in patients wtih persistent asthma
114. Patients on inhaled fluticasone 44 & 110 αg demonstrate significant reductions in both asthma and total health care costs while zafirlukast increases costs
115. Retrospective outcomes analysis of the effects of zafirlukast therapy in the management of patients with asthma in the US
116. The impact of singleagent controller therapies on asthma-related quality of life
117. The impact of fluticasone propionate and zafirlukast on patient quality of life
118. Zafirlukast (Accolate®) in moderate asthma: Patient-reported outcomes and peripheral eosinophil data from a 13-week trial
119. Greater improvements in quality of life (QoL) over 12 months with zafirlukast 20mg BD plus low dose steroids vs double-dose steroids in patients with greater QoL impairment
120. A comparison of patient preference for treatment with oral zafirlukast or inhaled beclomethasone
121. Compliance with an oral asthma medication: A pilot study using an electronic monitoring device
122. Treatment preferences of adolescent patients with asthma
123. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast
124. Tolerability of leukotriene modifiers in asthma: A review of clinical experience
125. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment
126. Zafirlukast and Churg-Strauss syndrome. Reply
127. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal?
128. Do antileukotrienes uncover Churg-Strauss syndrome?
129. Steroids and Churg-Strauss syndrome
130. Difficult asthma or Churg-Strauss syndrome? Steroids may be masking undiagnosed cases of Churg-Strauss syndrome
131. Churg-Strauss syndrome and antiasthma therapy
132. Churg-Strauss syndrome. Reply
133. Zafirlukast and Churg-Strauss syndrome
134. Churg-Strauss syndrome
135. Leukotriene modifiers and Churg-Strauss syndrome: An update
136. AstraZeneca revises zafirlukast (Accolate) labeling in the US
137. Guidelines update: Where do the new therapies fit in the management of asthma?
138. Improving outcomes in elderly patients with asthma
139. Comparison of patient's compliance with prescribed oral and inhaled asthma medications
140. Salmeterol compared with current therapies in chronic asthma
141. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol
142. Effect of long-term treatment with salmeterol on asthma control: A double blind, randomised crossover study
143. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma
144. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
145. Salmeterol tachyphylaxis in steroid treated asthmatic patients
146. Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol
147. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol
148. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients
149. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis